Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function
Not Applicable
Recruiting
- Conditions
- HPAAdrenal InsufficiencyHealthy Volunteer StudyCortisol Deficiency
- Interventions
- Drug: Placebo
- Registration Number
- NCT06608433
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Brief Summary
This study aims to investigate the effects of a single dose of the glucagon-like 1 receptor agonist semaglutdie/Rybelsus on the hypothalamo-pituitary-adrenal axis, thus cortisol levels and other stresshormones in healthy males.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 23
Inclusion Criteria
- Healthy male volunteers aged 18-60 years
- BMI 18.5-30 kg/m2
- No regular medication
Exclusion Criteria
- participation in a trial with investigational drugs within 30 days
- vigorous physical exercise within 24 hours before the study participation
- alcohol intake within 24 hours before the study participation
- a history of intake of glucocorticoids or GLP-1 RA within the last 8 weeks.
- Known allergy towards GLP-1 RA
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Placebo - Semaglutide/Rybelsus semaglutide -
- Primary Outcome Measures
Name Time Method Change in serum cortisol after Rybelsus vs. Placebo within 210 minutes after the intake of the study drug The primary endpoint is the difference between the two visits (placebo vs. Rybelsus) in the change in cortisol from cortisol baseline to the maximally stimulated cortisol value (cortisolmax).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Basel
🇨ðŸ‡Basel, Switzerland